NEWS
Celleo Ships First Larkem™ V40 System to Leading CAR-T Manufacturer
Celleo is proud to announce the shipment of its first Larkem V40 system to one of the world’s largest commercial producers of CAR-T cell therapies, located in the United States. This initial system will undergo a comprehensive technical evaluation ahead of future integration into the customer’s production lines. The shipment represents the beginning of a scheduled series of deliveries, underscoring Celleo’s ongoing commercial growth and success.
The Larkem V40 system is a state-of-the-art, automated, closed-system solution designed specifically for the critical Formulate + Fill stage in cell therapy production. In anticipation of a successful evaluation, the customer has already placed follow-up orders for multiple GMP-compliant systems. These production-ready units are slated for delivery in late 2025.
Operating within a fully sealed environment, the Larkem V40 significantly reduces the dependency on costly and limited cleanroom facilities, enabling manufacturers to rapidly increase their overall production capacity. The system drastically enhances efficiency, completing the Formulate + Fill process far quicker than manual methods. Beyond reducing costs and improving efficiency, this accelerated processing facilitates a quicker transition to cryopreservation, helping to preserve cell viability by minimising exposure time.
Other key advantages include the substantial reduction of manual handling errors and a lower risk of aseptic contamination—critical factors in cell therapy manufacturing.
Reflecting on this milestone, Celleo CEO David Kneen said: “The shipment of our first Larkem V40 system is a pivotal moment for Celleo, marking the culmination of three years of focused innovation and development by our outstanding team. This achievement not only validates our technology but also positions Celleo firmly at the forefront of advancing global capabilities in automated cell therapy manufacturing.”
Celleo is set to deliver additional evaluation systems to new customers over the coming months, further expanding its impact and presence within the cell therapy industry.
NEWS
Celleo Ships First Larkem™ V40 System to Leading CAR-T Manufacturer
Celleo is proud to announce the shipment of its first Larkem V40 system to one of the world’s largest commercial producers of CAR-T cell therapies, located in the United States. This initial system will undergo a comprehensive technical evaluation ahead of future integration into the customer’s production lines. The shipment represents the beginning of a scheduled series of deliveries, underscoring Celleo’s ongoing commercial growth and success.
The Larkem V40 system is a state-of-the-art, automated, closed-system solution designed specifically for the critical Formulate + Fill stage in cell therapy production. In anticipation of a successful evaluation, the customer has already placed follow-up orders for multiple GMP-compliant systems. These production-ready units are slated for delivery in late 2025.
Operating within a fully sealed environment, the Larkem V40 significantly reduces the dependency on costly and limited cleanroom facilities, enabling manufacturers to rapidly increase their overall production capacity. The system drastically enhances efficiency, completing the Formulate + Fill process far quicker than manual methods. Beyond reducing costs and improving efficiency, this accelerated processing facilitates a quicker transition to cryopreservation, helping to preserve cell viability by minimising exposure time.
Other key advantages include the substantial reduction of manual handling errors and a lower risk of aseptic contamination—critical factors in cell therapy manufacturing.
Reflecting on this milestone, Celleo CEO David Kneen said: “The shipment of our first Larkem V40 system is a pivotal moment for Celleo, marking the culmination of three years of focused innovation and development by our outstanding team. This achievement not only validates our technology but also positions Celleo firmly at the forefront of advancing global capabilities in automated cell therapy manufacturing.”
Celleo is set to deliver additional evaluation systems to new customers over the coming months, further expanding its impact and presence within the cell therapy industry.
